CanAg Diagnostics Overview

  • Founded
  • 1992
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

CanAg Diagnostics General Information

Description

Developer of immunological reagents. The company develops monoclonal antibodies for the treatment of cancer, brain damage and tumors.

Contact Information

Website
Formerly Known As
Centocor Diagnostics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare
Acquirer
Fujirebio Diagnostics
Primary Office
  • Elof Lindälvs gata 13
  • 414 55 Gothenburg
  • Sweden
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

CanAg Diagnostics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 31-May-2006 Completed Generating Revenue
2. Angel (individual) 01-Jan-2001 Completed Generating Revenue
1. Early Stage VC Completed Startup
To view CanAg Diagnostics’s complete valuation and funding history, request access »

CanAg Diagnostics Executive Team (3)

Name Title Board Seat Contact Info
Börje Karlsson Co-Founder
Leif Lindholm Co-Founder
To view CanAg Diagnostics’s complete executive team members history, request access »

CanAg Diagnostics Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Industrifonden Venture Capital Minority 000 0000 000000 0
Líftæknisjóðurinn MP BIO hf Venture Capital Minority 000 0000 000000 0
To view CanAg Diagnostics’s complete investors history, request access »